Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
about
Emerging therapies targeting intra-organ inflammation in transplantationProgress toward in vivo use of siRNAs-IITranslational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory DiseasesChemical modification: the key to clinical application of RNA interference?Bioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue.Specific up-regulation of p21 by a small active RNA sequence suppresses human colorectal cancer growthOcular delivery of pRNA nanoparticles: distribution and clearance after subconjunctival injection.Stimulation of ribosomal frameshifting by antisense LNADelivery of siRNA therapeutics: barriers and carriers.Corneal neovascularization: an anti-VEGF therapy review.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Efficient delivery of NF-κB siRNA to human retinal pigment epithelial cells with hyperbranched cationic polysaccharide derivative-based nanoparticlesOn future's doorstep: RNA interference and the pharmacopeia of tomorrow.Vascular endothelial growth factor in eye disease.Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.RNAi mechanisms and applicationsAge-dependent disease expression determines remodeling of the retinal mosaic in carriers of RPGR exon ORF15 mutationsRNA interference and micro RNA-oriented therapy in cancer: rationales, promises, and challenges.Ocular drug delivery for glaucoma management.Chitosan nanoparticles for drug delivery to the eye.Drug delivery systems for the eye.Ocular drug delivery - a look towards nanobioadhesives.Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals.Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics.Delivery of RNAi therapeutics: work in progress.Liposomal siRNA nanocarriers for cancer therapy.Dendrimers for gene delivery--a potential approach for ocular therapy?Nanocarriers of nanotechnology in retinal diseases.Tubocapsanolide A inhibits transforming growth factor-beta-activating kinase 1 to suppress NF-kappaB-induced CCR7.Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy.Barriers to Liposomal Gene Delivery: from Application Site to the Target.A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization.siRNA-loaded liposomes: Inhibition of encystment of Acanthamoeba and toxicity on the eye surface.Delivery of nucleic acids.Electrically assisted delivery of macromolecules into the corneal epithelium.Glutathione-responsive nano-transporter-mediated siRNA delivery: silencing the mRNA expression of Ras.Effects of CD25siRNA gene transfer on high-risk rat corneal graft rejection.Reducible Polyethylenimine Nanoparticles for Efficient siRNA Delivery in Corneal Neovascularization Therapy.Measuring the intravitreal mobility of nanomedicines with single-particle tracking microscopy.Knockdown of TNF‑α alleviates acute lung injury in rats with intestinal ischemia and reperfusion injury by upregulating IL‑10 expression.
P2860
Q28085496-1763ABD9-82EE-4C2E-9315-3F742A373FA4Q28255877-5AF567CB-C0EB-4BE4-8FAB-50915363D669Q28548580-5D5E0143-A68A-4636-9987-0A7067AF0785Q33308712-8BB52DA8-13A1-4C4F-8580-69B56000DE34Q33321483-0ECEE3E4-3CFC-4645-8B61-192924442AE1Q33648752-407EEE78-2D22-4F31-8F08-E31AA8463C05Q34011377-5BDBB0AB-AFC9-48D9-8C91-78E072E530D1Q34023372-E92448FE-765C-4FB3-87C7-80E4522B44FCQ34293708-2CB621B6-416F-4BD8-9318-3EA16A682742Q34641522-15C1398C-B970-4D28-9A30-9CC7B03135F0Q35205410-2511AF93-2F80-4606-9440-F0EF6532CA59Q35411181-6B7EF386-2DBB-4AA3-91AB-7565E2BF82A5Q36173624-F78F3C35-C389-4B52-9F35-8667C90A65DFQ36929380-4552FB0A-4A6F-4ADF-92C4-DB5C49803C29Q37109083-0678C5A3-5E3C-454B-A19B-10CB805F31D0Q37161379-C2147460-61CD-432F-93EF-8EA87269964BQ37281623-0E346F75-EBA6-49CB-9F42-C999CD68AB21Q37292432-61559C0F-2F16-49B5-B489-992657B3BF95Q37327814-7188DBDA-9E72-43A2-BC79-35271F255ABAQ37416144-5BA95A7F-BBAA-48E0-B967-49451D769320Q37472106-8E25595A-A345-4C14-9D9B-BDAD84ADBDA6Q37822756-D1543705-EB17-478C-88DF-2D00C23B6943Q37882685-934D4959-DC1B-4436-91F2-DF5B3CECD758Q37942156-246715E9-D94C-4BB5-AF99-6D925E7BBC58Q38160246-92E3ACB8-6481-4D04-9F18-D81ED9A160AEQ38175250-59A52AA1-CD34-48F7-8C4D-400FB7BE8A43Q38196447-627E495E-A340-4809-9819-CDFE19DC7C9FQ38282885-77944F36-5BD2-4879-84F7-CBEF217D25C5Q38358496-72CD9C89-D8B3-46B4-A03C-42546D63948DQ39066848-C8E5123F-1774-4763-B500-6FEDFB5EEA8EQ39147224-5CED3905-9B95-4565-BAC2-385B0C23F16BQ39706540-711EAF8D-F58B-48E2-ADC4-B63AAB4940BAQ40353236-7C985103-0F3B-434E-9EC7-C6EEF57B743CQ42115283-3E699FAE-ECCD-4028-ACC0-34E45B1D0D32Q42914104-746736F3-764A-4328-9C1E-03798A702210Q44791097-1ADF3B42-EED8-4456-8B16-737E864DA62BQ45876389-BE298E28-ABC4-46EC-82CD-496C641D64F9Q47610066-86A38FAC-BE88-4889-A3A4-7A1702800719Q48735724-0489D4CE-3DBF-4399-A58D-E3A9B08E06F0Q54088668-9F5DC2E2-C7E6-47F3-93BB-8335A0C8BEBB
P2860
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
@ast
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
@en
type
label
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
@ast
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
@en
prefLabel
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
@ast
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA.
@en
P1476
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA
@en
P2093
Amélie Bochot
Elias Fattal
P304
P356
10.1016/J.ADDR.2006.07.020
P407
P577
2006-09-15T00:00:00Z